HemCon Medical Technologies, a developer of advanced medical products, has announced improved results from an independent study investigating the time required to successfully treat fungal infected human nails which is a leading cause of onychomycosis, the most common type of fungal nail infection.
The studies were conducted as part of HemCon’s continued program of development for a formulation based on its newest Mycosinate platform technology. The onychomycosis treatment, Mycosinate is available for commercial license and provides a controlled release broad spectrum antimicrobial agent to fight infection, said HemCon.
The independent testing of Mycosinate for the treatment of onychomycosis was performed using fungal infected human nails under conditions that simulate the clinical situation. This system tests the formulations ability to penetrate the nail and kill the Trichophyton rubrum fungal infection on human nails over a period of time.
Results observed complete kill of the fungal infection in 14 days. The latest study results indicate that cell viability of the infecting organism (T rubrum) was reduced to 52% on day three of treatment and further reduced to 5.3% on day seven of treatment with the active Mycosinate formulation. A complete kill of the infection was observed at day 14 of treatment, the company said.
John Morgan, CEO of HemCon, said: HemCon’s fourth study in live human nail infection further validates the superior abilities of Mycosinate compared to solutions on the market, to safely and effectively treat the millions of people afflicted with fungal nail infections. This platform to treat nail infections provides us with a promising technology in a robust and growing market.